SavedAdd your journal

Journals / Turkish Journal of Obstetrics and Gynecology / 2019 / Cilt: 16 - Sayı: 4

The potential of serum fetal DNA for early diagnosis of gestational trophoblastic disease

Gestasyonal trofoblastik hastalığın erken tanısında serum fetal DNA’nın potansiyeli

Hüseyin Çağlayan ÖZCAN
Seyhun SUCU
Özcan BALAT
Mehmet OBUT
Muhammed Hanifi BADEMKIRAN
Fatma Bahar CEBESOY
Pages
249–254
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This indicates that maternal peripheral bloodstream cfDNA monitoring might be significant in the early diagnosis of GTD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To study cell-free DNA (cfDNA) levels in patients with gestational trophoblastic disease (GTD) in order to test the hypothesis that cfDNA circulating inmaternal plasma could provide early detection of GTD.Materials and Methods: This study included 32 patients with GTD (complete mole and partial mole) and 30 non-GTD patients in the first trimester of pregnancywith no other medical problems. cfDNA levels in maternal serum were measured using polymerase chain reaction analysis on Y-chromosome–specific sequences.Results: cfDNA was found as 327±367 pg on average in the control group and 600±535 pg in the GTD group.
📊
Key Findings & Data:Within the GTD group, the partial mole grouphad an cfDNA average of 636±549 pg, and the complete mole group had an cfDNA average of 563±536 pg.
💡
Conclusion & Impact:This indicates that maternal peripheral bloodstream cfDNA monitoring might be significant in the early diagnosis of GTD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To study cell-free DNA (cfDNA) levels in patients with gestational trophoblastic disease (GTD) in order to test the hypothesis that cfDNA circulating inmaternal plasma could provide early detection of GTD.Materials and Methods: This study included 32 patients with GTD (complete mole and partial mole) and 30 non-GTD patients in the first trimester of pregnancywith no other medical problems. cfDNA levels in maternal serum were measured using polymerase chain reaction analysis on Y-chromosome–specific sequences.Results: cfDNA was found as 327±367 pg on average in the control group and 600±535 pg in the GTD group. Within the GTD group, the partial mole grouphad an cfDNA average of 636±549 pg, and the complete mole group had an cfDNA average of 563±536 pg. Although there was a statistically significant differencebetween the GTD group and the control group in terms of cfDNA (p=0.02), there was no statistically significant difference between the complete mole group andthe partial mole group (p=0.76).Conclusion: Non-parametric analysis of covariance in terms of cfDNA in GTD was performed, thereby increasing its power and revealing a significant differencecompared with the control group. This indicates that maternal peripheral bloodstream cfDNA monitoring might be significant in the early diagnosis of GTD.

Özet

Amaç: Maternal plazmada dolaşan serum fetal DNA’nın (cfDNA) gestasyonel trofoblastik hastalığın (GTH) erken tanısında potansiyeli olduğunu tespit etmek için GTH’de cfDNA düzeylerini inceledik. Gereç ve Yöntemler: Çalışmaya, gebeliğin ilk üç ayında diğer tıbbi problemleri olmayan 32 GTH hastası (komplet mol ve inkomplet mol) ve GTH olmayan 30 hasta dahil edildi. Maternal serumdaki cfDNA seviyeleri, Y-kromozomuna spesifik dizinlerde polimeraz zincir reaksiyonu analizi kullanılarak ölçüldü. Bulgular: Kontrol grubunda cfDNA ortalama olarak 327±367 pg, GTH grubunda 600±535 pg olarak bulundu. GTH grubunda Inkomplet mol grubu cfDNA ortalaması 636±549 pg idi ve komplet mol grubu cfDNA ortalaması 563±536 pg idi. GTH grubu ile kontrol grubu arasında istatistiksel olarak anlamlı bir fark vardı (p=0,02). cfDNA açısından, komplet mol grubu ile inkomplet mol grubu arasında istatistiksel olarak anlamlı bir fark bulunmadı (p=0,76). Sonuç: GTH’de cfDNA açısından kontrol grubuyla karşılaştırıldığında anlamlı bir fark ortaya çıktı. Bu maternal periferik kan akımı cfDNA izlemenin GTH’nin erken tanısında önemli olabileceğini göstermektedir.

🔖

Cite This Article

ÖZCAN, H. Ç., SUCU, S., BALAT, Ö., OBUT, M., BADEMKIRAN, M. H., CEBESOY, F. B. (2022). The potential of serum fetal DNA for early diagnosis of gestational trophoblastic disease. Turkish Journal of Obstetrics and Gynecology, Cilt: 16 - Sayı: 4, 249–254. https://ajindex.com/articles/613008

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Coletta JM, Hou JY. 104-Gestational Trophoblastic Disease. Second Edi. Obstetric Imaging: Fetal Diagnosis and Care: Second Edition. Elsevier Inc.; 2017.449-452.e1 s
  2. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, et al. Free DNA and carcinoembryonic antigen serum levels: An important combination for diagnosis of colorectal cancer. Clin Cancer Res 2006;12:6985-8
  3. Xue X, Teare MD, Holen I, Zhu YM, Woll PJ. Optimizing the yield and utility of circulating cell-free DNA from plasma and serum. Clin Chim Acta 2009;404:100-4
  4. Wichmann D, Panning M, Quack T, Kramme S, Burchard G-D, Grevelding C, et al. Diagnosing Schistosomiasis by Detection of Cell-Free Parasite DNA in Human Plasma. Correa-Oliveira R, editör. PLoS Negl Trop Dis 2009;3:e422
  5. Litton C, Stone J, Eddleman K, Lee M-J. Noninvasive Prenatal Diagnosis: Past, Present, and Future. Mt Sinai J Med A J Transl Pers Med 2009;76:521-8
  6. Lazar L, Rigó J, Nagy B, Balogh K, Makó V, Cervenak L, et al. Relationship of circulating cell-free DNA levels to cell-free fetal DNA levels, clinical characteristics and laboratory parameters in preeclampsia. BMC Med Genet 2009;10:120
  7. Lo YMD, Leung TN, Tein MSC, Sargent IL, Zhang J, Lau TK, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-8
  8. Zhang J, Lau TK, Leung TN, Lo YMD, Hjelm NM. Maternal plasma fetal DNA as a marker for preterm labour. Lancet 2005;352:1904-5
  9. González-González MC, Trujillo MJ, Rodríguez de Alba M, GarcíaHoyos M, Lorda-Sánchez I, Díaz-Recasens J, et al. Huntington disease-unaffected fetus diagnosed from maternal plasma using QFPCR. Prenat Diagn 2003;23:232-4
  10. Chiu RWK, Lau TK, Cheung PT, Gong ZQ, Leung TN, Lo YMD. Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study. Clin Chem 2002;48:778-80
  11. Hardison RC, Chui DHK, Giardine B, Riemer C, Patrinos GP, Anagnou N, et al. HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat 2002;19:225-33
  12. Sekizawa A, Jimbo M, Saito H, Iwasaki M, Sugito Y, Yukimoto Y, et al. Increased cell-free fetal DNA in plasma of two women with invasive placenta. Clin Chem 2002;48:353-4
  13. Sekizawa A, Sugito Y, Iwasaki M, Watanabe A, Jimbo M, Hoshi S, et al. Cell-free fetal DNA is increased in plasma of women with hyperemesis gravidarum. Clin Chem 2001;47:2164-5
  14. Caramelli E, Rizzo N, Concu M, Sim